General information. Data from INVIMA’s public register, checked 16 October 2026. bioaccess® is not affiliated with any CRO listed.
Sponsors often ask which CROs actually run trials in Colombia. Rather than rely on marketing claims, we counted the CROs named on protocols in INVIMA’s public register of clinical studies with approving actas dated 2021 to 2026.
Ranking
| # | CRO named in INVIMA register | Protocols, actas 2021–2026 |
|---|---|---|
| 1 | IQVIA RDS Colombia | 45 |
| 2 | PPD Colombia (Thermo Fisher) | 41 |
| 3 | Parexel International Colombia | 20 |
| 4 | ICON Clinical Research Colombia | 11 |
| 5 | PRA Health Sciences Colombia (now part of ICON) | 9 |
| 6 | Fortrea / Covance / Labcorp Colombia | 8 |
| 7 | PSI CRO Colombia | 7 |
| 8 | Intrials | 7 |
| 9 | Syneos Health Colombia | 6 |
| 10 | ReSolution Latin America | 6 |
| 11 | Worldwide Clinical Trials Colombia | 5 |
| 12 | Alvarez Gotuzzo Asociados | 4 |
| 13 | CTI Clinical | 3 |
| 14 | Vaxtrials Colombia | 2 |
Method: one count per protocol per CRO; name variants merged (for example, “IQVIA RDS Colombia S.A.S.” and “IQVIA RDS COLOMBIA SAS”). Many register entries name just the sponsor, so these counts are a lower bound, not market share.
What the data says
- Large global CROs dominate drug and biologic protocols in Colombia.
- Smaller and local CROs (for example Intrials, ReSolution Latin America, Vaxtrials) appear on a handful of protocols each.
- Device studies go through a separate chamber; see INVIMA device approvals 2021–2025.
Where bioaccess® fits
bioaccess® serves biopharma, biotech and radiopharma startups running first-in-human and early-phase studies, where a large global CRO can be a poor fit for budget and speed. It operates in Colombia through Bioaccess Colombia SAS.
Frequently asked questions
Which CROs run the most drug trials in Colombia?
Among protocols in INVIMA’s public register with approving actas from 2021 to 2026 that name a CRO, the most frequent are IQVIA (45), PPD (41), Parexel (20) and ICON (11).
How was this ranking built?
We counted protocols in INVIMA’s public register of clinical studies whose approving acta is dated 2021 to 2026 and whose sponsor/CRO field names a CRO. Many entries name just the sponsor, so counts are a lower bound.
Where do device CROs appear?
Device studies are reviewed by a different INVIMA chamber. See our page on INVIMA device clinical trial approvals 2021–2025.
Related pages
- Clinical trials in Colombia
- CRO in Colombia
- First-in-human trials in Colombia
- INVIMA clinical trial approval process
- Clinical trial cost in Colombia
Next step
Comparing CROs for a Colombian study? Schedule time with Julio G. Martinez-Clark, CEO of bioaccess®.